Related Experiment Video
Updated: Nov 15, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic Cell-Based Immunotherapy in Lung Cancer
Dieter Stevens1,2, Joline Ingels3, Sandra Van Lint2,4
1Respiratory Medicine - Thoracic Oncology Cluster, Ghent University Hospital, Ghent, Belgium.
Abstract:
Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients derive clinical benefit from these treatments suggesting that the full anti-tumoral potential of the immune system is not being harnessed yet. One way to overcome this problem is to combine immune checkpoint blockade with different strategies aimed at inducing or restoring cellular immunity in a tumor-specific, robust, and durable way. Owing to their unique capacity to initiate and regulate T cell responses, dendritic cells have been extensively explored as tools for immunotherapy in many tumors, including lung cancer. In this review, we provide an update on the nearly twenty years of experience with dendritic cell-based immunotherapy in lung cancer. We summarize the main results from the early phase trials and give an overview of the future perspectives within this field.
Insights
Dendritic cell immunotherapy shows promise for lung cancer treatment, enhancing immune responses beyond current checkpoint inhibitors. This review explores nearly two decades of research and future directions for this approach.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Immune checkpoint inhibitors have advanced metastatic lung cancer treatment but benefit a minority of patients.
- There is a need to enhance anti-tumoral immunity for broader patient benefit.
Purpose of the Study:
- To review the 20-year experience with dendritic cell-based immunotherapy in lung cancer.
- To summarize findings from early-phase clinical trials.
- To discuss future perspectives for dendritic cell therapy in lung cancer.
Main Methods:
- Review of early-phase clinical trials and scientific literature.
- Analysis of dendritic cell function in initiating and regulating T cell responses.
- Exploration of combination strategies with immune checkpoint blockade.
Main Results:
- Dendritic cells are potent tools for initiating and regulating T cell responses.
- Early trials have explored dendritic cell immunotherapy in various tumors, including lung cancer.
- Despite challenges, dendritic cell therapy holds potential for enhancing anti-tumoral immunity.
Conclusions:
- Dendritic cell-based immunotherapy is a promising strategy to overcome limitations of current lung cancer treatments.
- Combining dendritic cell therapy with immune checkpoint inhibitors may harness the full anti-tumoral potential of the immune system.
- Further research and clinical trials are needed to optimize dendritic cell immunotherapy for lung cancer patients.
